These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 24448226

  • 1. Beyond greyscale IVUS assessment of progression/regression: it should be simple, but it's not.
    Mintz GS.
    Eur Heart J Cardiovasc Imaging; 2014 Apr; 15(4):378-9. PubMed ID: 24448226
    [No Abstract] [Full Text] [Related]

  • 2. Comparison of effects of atorvastatin (20 mg) versus rosuvastatin (10 mg) therapy on mild coronary atherosclerotic plaques (from the ARTMAP trial).
    Lee CW, Kang SJ, Ahn JM, Song HG, Lee JY, Kim WJ, Park DW, Lee SW, Kim YH, Park SW, Park SJ.
    Am J Cardiol; 2012 Jun 15; 109(12):1700-4. PubMed ID: 22440123
    [Abstract] [Full Text] [Related]

  • 3. Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN.
    Puri R, Libby P, Nissen SE, Wolski K, Ballantyne CM, Barter PJ, Chapman MJ, Erbel R, Raichlen JS, Uno K, Kataoka Y, Tuzcu EM, Nicholls SJ.
    Eur Heart J Cardiovasc Imaging; 2014 Apr 15; 15(4):380-8. PubMed ID: 24448227
    [Abstract] [Full Text] [Related]

  • 4. Comparison of effects of rosuvastatin and atorvastatin on plaque regression in Korean patients with untreated intermediate coronary stenosis.
    Hong YJ, Jeong MH, Hachinohe D, Ahmed K, Choi YH, Cho SH, Hwang SH, Ko JS, Lee MG, Park KH, Sim DS, Yoon NS, Yoon HJ, Kim KH, Park HW, Kim JH, Ahn Y, Cho JG, Park JC, Kang JC.
    Circ J; 2011 Apr 15; 75(2):398-406. PubMed ID: 21157106
    [Abstract] [Full Text] [Related]

  • 5. Factors underlying regression of coronary atheroma with potent statin therapy.
    Puri R, Nissen SE, Ballantyne CM, Barter PJ, Chapman MJ, Erbel R, Libby P, Raichlen JS, St John J, Wolski K, Uno K, Kataoka Y, Nicholls SJ.
    Eur Heart J; 2013 Jun 15; 34(24):1818-25. PubMed ID: 23644179
    [Abstract] [Full Text] [Related]

  • 6. Comment on Stegman et al. High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN. Diabetes Care 2014;37:3114-3120.
    Huang BT, Chen M.
    Diabetes Care; 2015 Feb 15; 38(2):e27. PubMed ID: 25614700
    [No Abstract] [Full Text] [Related]

  • 7. Response to Comment on Stegman et al. High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN. Diabetes Care 2014;37:3114-3120.
    Stegman B, Puri R, Shao M, Nicholls SJ.
    Diabetes Care; 2015 Feb 15; 38(2):e28-9. PubMed ID: 25614701
    [No Abstract] [Full Text] [Related]

  • 8. Effect of two intensive statin regimens on progression of coronary disease.
    Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, Raichlen JS, Uno K, Borgman M, Wolski K, Nissen SE.
    N Engl J Med; 2011 Dec 01; 365(22):2078-87. PubMed ID: 22085316
    [Abstract] [Full Text] [Related]

  • 9. From CARDS to AURORA: one disease, two responses.
    Escobar C, Barrios V, Echarri R.
    Hellenic J Cardiol; 2010 Dec 01; 51(3):281. PubMed ID: 20515865
    [No Abstract] [Full Text] [Related]

  • 10. Is rosuvastatin really a more efficient therapeutic option than atorvastatin?
    Soto J, Fernandez de Bobadilla J.
    Value Health; 2006 Dec 01; 9(4):276-7; author reply 277-9. PubMed ID: 16903999
    [No Abstract] [Full Text] [Related]

  • 11. [Symptomatic coronary heart disease. Impressive plaque reduction with high dose statins].
    Einecke D.
    MMW Fortschr Med; 2011 Dec 08; 153(49-50):18. PubMed ID: 22308585
    [No Abstract] [Full Text] [Related]

  • 12. High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN.
    Stegman B, Puri R, Cho L, Shao M, Ballantyne CM, Barter PJ, Chapman MJ, Erbel R, Libby P, Raichlen JS, Uno K, Kataoka Y, Nissen SE, Nicholls SJ.
    Diabetes Care; 2014 Nov 08; 37(11):3114-20. PubMed ID: 25190674
    [Abstract] [Full Text] [Related]

  • 13. [Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): -- the PATROL trial].
    Saku K, Zhang B, Noda K.
    Nihon Naika Gakkai Zasshi; 2011 Dec 10; 100(12):3679-86. PubMed ID: 22338904
    [No Abstract] [Full Text] [Related]

  • 14. Dramatic reductions in plaque volumes on maximum statin therapy.
    Cardiovasc J Afr; 2011 Dec 10; 22(6):344-5. PubMed ID: 22159326
    [No Abstract] [Full Text] [Related]

  • 15. NLRP3 inflammasome activation in coronary artery disease: results from prospective and randomized study of treatment with atorvastatin or rosuvastatin.
    Satoh M, Tabuchi T, Itoh T, Nakamura M.
    Clin Sci (Lond); 2014 Feb 10; 126(3):233-41. PubMed ID: 23944632
    [Abstract] [Full Text] [Related]

  • 16. [Comment from the cardiologic viewpoint].
    Lüscher TF.
    Praxis (Bern 1994); 2009 Feb 04; 98(3):129-30. PubMed ID: 19180438
    [No Abstract] [Full Text] [Related]

  • 17. [High lowering of lipids can melt coronary plaques -- is coronary disease reversible?].
    Einecke D.
    MMW Fortschr Med; 2006 Jun 15; 148(24):4-5. PubMed ID: 16850796
    [No Abstract] [Full Text] [Related]

  • 18. High coronary plaque load: a heavy burden.
    de Graaf MA, Jukema JW.
    Eur Heart J; 2013 Nov 15; 34(41):3168-70. PubMed ID: 23966308
    [No Abstract] [Full Text] [Related]

  • 19. Strong statins as the major players for dyslipidemia in high-risk patients: are they all the same or not?
    Ikewaki K, Ayaori M.
    Circ J; 2011 Nov 15; 75(6):1326-7. PubMed ID: 21532174
    [No Abstract] [Full Text] [Related]

  • 20. A meta-analysis of randomized head-to-head trials of atorvastatin versus rosuvastatin for reductions in C-reactive protein.
    Takagi H, Umemoto T.
    Int J Cardiol; 2012 Jan 12; 154(1):78-81. PubMed ID: 22019059
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.